Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary?
Büchner T, Hiddemann W, Wörmann B, Löffler H, Ludwig WD, Schoch C, Haferlach T, Maschmeyer G, Staib P, Aul C, Heyll GA, Grüneisen A, Rasche H, Eimermacher JH, Balleisen L, Pielken HJ, Reis HE, Griesinger F, Reichle A, Sauerland MC, Heinecke A; German AMLCG. Büchner T, et al. Among authors: gruneisen a. Int J Hematol. 2000 Oct;72(3):285-9. Int J Hematol. 2000. PMID: 11185983
Acute myeloid leukemia: treatment over 60.
Büchner T, Hiddemann W, Berdel W, Wörmann B, Schoch C, Löffler H, Haferlach T, Schumacher A, Staib P, Balleisen L, Grüneisen A, Rasche H, Aul C, Heyll A, Lengfelder E, Ludwig WD, Maschmeyer G, Eimermacher H, Karow J, Frickhofen N, Hirschmann WD, Sauerland MC; German AML Co-Operative Group. Büchner T, et al. Among authors: gruneisen a. Rev Clin Exp Hematol. 2002 Mar;6(1):46-59; discussion 86-7. doi: 10.1046/j.1468-0734.2002.00059.x. Rev Clin Exp Hematol. 2002. PMID: 12060483 Review.
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A; German AML Cooperative Group. Büchner T, et al. Among authors: gruneisen a. J Clin Oncol. 2003 Dec 15;21(24):4496-504. doi: 10.1200/JCO.2003.02.133. J Clin Oncol. 2003. PMID: 14673036 Clinical Trial.
Treatment of older patients with AML.
Büchner T, Berdel WE, Wörmann B, Schoch C, Haferlach T, Schnittger S, Kern W, Aul C, Lengfelder E, Schumacher A, Reichle A, Staib P, Balleisen L, Eimermacher H, Grüneisen A, Rasche H, Sauerland MC, Heinecke A, Mesters RM, Serve HL, Kienast J, Hiddemann W. Büchner T, et al. Among authors: gruneisen a. Crit Rev Oncol Hematol. 2005 Nov;56(2):247-59. doi: 10.1016/j.critrevonc.2004.09.010. Epub 2005 Oct 21. Crit Rev Oncol Hematol. 2005. PMID: 16246568 Review.
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W. Büchner T, et al. Among authors: gruneisen a. J Clin Oncol. 2009 Jan 1;27(1):61-9. doi: 10.1200/JCO.2007.15.4245. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047294 Clinical Trial.
Remission induction therapy: the more intensive the better?
Büchner T, Hiddemann W, Berdel W, Wörmann B, Löffler H, Schoch C, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Andreesen R, Balleisen L, Haase D, Eimermacher H, Aul C, Rasche H, Uhlig J, Grüneisen A, Reis HE, Hartlapp J, Hirschmann WD, Weh HJ, Pielken HJ, Gassmann W, Sauerland MC, Heinecke A. Büchner T, et al. Among authors: gruneisen a. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S41-4. doi: 10.1007/s002800100305. Cancer Chemother Pharmacol. 2001. PMID: 11587366
Subgroup specific therapy effects in AML: AMLCG data.
Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Balleisen L, Grüneisen A, Aul C, Lengfelder E, Hehlmann R, Kern W, Serve HL, Mesters RM, Eimermacher H, Frickhofen N, Kienast J, Giagounidis A, Sauerland MC, Heinecke A; German AMLCG. Büchner T, et al. Among authors: gruneisen a. Ann Hematol. 2004;83 Suppl 1:S100-1. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124694 No abstract available.
Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.
Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T. Krug U, et al. Among authors: gruneisen a. Leukemia. 2016 Jun;30(6):1230-6. doi: 10.1038/leu.2016.25. Epub 2016 Feb 9. Leukemia. 2016. PMID: 26859081 Clinical Trial.
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.
Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W. Büchner T, et al. Among authors: gruneisen a. Leukemia. 2016 Aug;30(8):1781-4. doi: 10.1038/leu.2016.54. Epub 2016 Mar 11. Leukemia. 2016. PMID: 26965440 Clinical Trial. No abstract available.
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W. Haferlach T, et al. Among authors: gruneisen a. J Clin Oncol. 2003 Jan 15;21(2):256-65. doi: 10.1200/JCO.2003.08.005. J Clin Oncol. 2003. PMID: 12525517
25 results